STAAR Surgical Company (STAA) Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Net Sales: $57.8 million, up from $49 million in Q4 2024.

China Net Sales: $17.5 million, significantly improved from $7.8 million in Q4 2024, but below expectations due to inventory adjustments.

Gross Profit Margin: Increased to 75.7% from 64.7% year-over-year, attributed to cost reductions and improved manufacturing efficiencies.

Operating Expenses: Totaled $66.6 million, including $11.2 million related to the terminated Alcon merger. Excluding these costs, operating expenses were $54.7 million, an 8.2% reduction from the previous year.

Adjusted EBITDA: Loss of $200,000, an improvement from a loss of $20.8 million in Q4 2024.

Cash Position: Approximately $187.5 million in cash and equivalents, stable since Q2 2025, with no debt.

2Strategic Updates and Business Highlights

Transition to a new leadership structure with Warren Foust and Deborah Andrews as Interim Co-CEOs.

Focus on stabilizing operations post-Alcon merger discussions, with a renewed emphasis on growth, profitability, and innovation.

Positive momentum in refractive surgery markets, particularly with the EVO ICL gaining market share as laser vision correction declines.

Successful launch of EVO+ in China, with plans for expanded commercial availability of the Lioli injector in EMEA.

Ongoing implementation of Oracle ERP to enhance operational efficiency and decision-making.

3Forward Guidance and Outlook

No specific financial guidance for 2026, but expectations for significant sales growth compared to 2025.

Targeting profitability in FY 2026, driven by increased sales and maintained cost discipline.

Anticipated slight decrease in gross margins due to higher costs from Swiss manufacturing and increased inventory reserves.

Cash generation expected to resume in the latter half of 2026, with a projected higher cash balance by year-end.

4Bad News, Challenges, or Points of Concern

China Market Dynamics: Despite recovering demand, uncertainties regarding inventory management and macroeconomic conditions remain.

Sales Disruptions: Distributor inventory adjustments negatively impacted Q4 sales, with concerns about future inventory levels and distributor confidence.

Competitive Pressures: The market for lens-based procedures is growing, but competition is intensifying, particularly from non-Collamer lenses.

Operational Challenges: The company faced difficulties in managing inventory levels and visibility in the past, which they are now addressing.

5Notable Q&A Insights

Distributor Inventory: Inventory levels have stabilized, with improvements noted in early 2026, suggesting readiness for market recovery.

Growth Projections: While optimistic about growth, management cautioned against expecting pre-2025 hyper growth levels, aiming instead for steady recovery.

Innovation Focus: Emphasis on bringing new products to market, with ongoing projects in the pipeline, though specific timelines were not disclosed.

Organizational Health: Employee morale is reportedly high post-Alcon merger discussions, with no unusual turnover reported. Overall, STAAR Surgical is positioned for a recovery in 2026, focusing on operational efficiency, market expansion, and innovation, despite facing challenges in inventory management and competitive pressures.